Form 4 Filing for Arcus Biosciences, Inc.

David L. Lacey, a director at Arcus Biosciences, Inc. (RCUS), acquired 5,700 shares of Common Stock and was granted 16,900 stock options on June 11, 2026. The Common Stock acquisition was made at a price of $0.0 per share, bringing the total post-transaction shares to 76,652. The stock options, with an exercise price of $23.30, also have a $0.0 acquisition price and vest on June 11, 2027, or earlier upon a change in control. Both the stock acquisition and option grant are marked as direct ownership.